



Multiple Sclerosis: DMT Switching (US & EU)

OVERVIEW

Multiple Sclerosis (MS) is a complex disease that does not have clearly established treatment patterns. While the availability of multiple therapeutic tools is theoretically beneficial to the patient and neurologist, deciphering which treatment is best for which patient and when to initiate or switch therapies is a major challenge. With diagnosis occurring earlier in the disease course, patients will potentially cycle through multiple therapies. Understanding when, why and to which product a neurologist will transition is critical to building a commercial strategy.

RealWorld Dynamix: DMT Switching in MS will help you evaluate this critical point in a patient journey. The study blends physician survey data (“what they say”) with patient record data (“what they do”) to understand which products are positioned by the doctor in which patient.

SAMPLE & METHODOLOGY

RealWorld Dynamix: DMT Switching in MS is based on an online survey of ~100 practicing neurologists per region, combined with a retrospective analysis of ~1000 patient records. Each physician completes an in-depth medical history of their last 5-10 patients who met the study inclusion criteria (patients recently switched to another DMT).

The patient pathway is retrieved back to the first referral with a more intensive analysis of the past twelve months. In addition to patient demographics and treatment history, clinical value drivers are included.

KEY QUESTIONS ANSWERED

- How common is DMT switching among MS patients?
- Which DMT brands are gaining and which are losing in a switch scenario?
- How long are patients treated with their first line before switching?
- What are the differences between EU countries on brand switching?
- What are the reasons neurologists choose specific brands to switch to? What role does the patient play in driving switching?

KEY DATES

For Both US & EU Reports:

- Comments & Proprietary Questions due: Oct 16
- Report Publishes: Dec 16

Products Profiled:

Commercial Products*:

Bayer (Betaseron), Biogen (Avonex, Plegridy, Tecfidera, Tysabri), EMD Serono (Rebif), Genzyme (Aubagio, Lemtrada), Novartis (Gilenya, Extavia), Sandoz/Momenta (**Glatopa), Teva (Copaxone)

Pipeline Agents:

Active Biotech /Teva (Laquinimod), Biogen/PDL BioPharma/Abbvie (Daclizumab), Roche/Genentech (Ocrelizumab), Genmab/GSK (Ofatumumab), Novartis (Siponimod), Biogen (Anti-LINGO), Receptos (RPC1063)

**Brand names and trademarks of products approved and indicated for Multiple Sclerosis. ** Glatopa is only approved in USA.*

Deliverables:

- PowerPoint Deck
- De-identified database in SPSS or Excel
- Up to 10 custom analyses & 10 custom subgroups built into database

Related Reports:

- RealWorldDynamix: DMT New Starts in MS US 2016
- RealWorldDynamix: DMT New Starts in MS EU5 2016
- RealTimeDynamix: Multiple Sclerosis US
- RealTimeDynamix: Multiple Sclerosis EU